| 1. |
-
- 2019
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
- Haw, Shu Chih, et al.
(författare)
-
Single antiferromagnetic axis of Fe in orthorhombic YMn0.5Fe0.5O3 films observed by x-ray magnetic linear dichroism
- 2019
-
Ingår i: Journal of Alloys and Compounds. - : Elsevier BV. - 0925-8388. ; 780, s. 79-84
-
Tidskriftsartikel (refereegranskat)abstract
- The electronic and magnetic structure of orthorhombic (o-) YMn0.5Fe0.5O3 (YMFO) epitaxial film (space group Pbnm) deposited on the YAlO3 (010) substrate have been investigated using linear polarization-dependent x-ray absorption spectroscopy and magnetization measurements. The magnetic-ordering temperature of around 280 K is observed in o-YMFO film. The x-ray absorption spectra at the Fe-K and the Mn-K edges indicate the existence of anisotropic crystal field in o-YMFO film, with the longest and shortest Fe–O and Mn–O bonds tend to align with the crystallographic b- and a-axis, respectively, whereas the medium Fe(Mn)–O bond is aligned with the c-axis. The experimental x-ray magnetic linear dichroism at the Fe-L2 edges demonstrate an unusual single antiferromagnetic axis of Fe3+ ions below magnetic-ordering temperature, while a multi antiferromagnetic axis is generally observed in o-RFeO3 (R = rare earth) thin films. Our configuration-interaction cluster calculations also reveal that the single antiferromagnetic axis of the Fe sublattice is aligned with the b-axis in o-YMFO film, whereas it is directed along the a-axis in the bulk o-YFeO3.
|
|
| 3. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 4. |
- Wang, Chang, et al.
(författare)
-
Molecular beam epitaxy growth of AlAs 1-x Bi x
- 2019
-
Ingår i: Semiconductor Science and Technology. - : IOP Publishing. - 1361-6641 .- 0268-1242. ; 34:3
-
Tidskriftsartikel (refereegranskat)abstract
- High quality AlAs 1-x Bi x layers with Bi composition of 3%-10.5% have been successfully grown by molecular beam epitaxy. The Bi incorporation is confirmed by Rutherford backscattering spectroscopy. For a 400 nm thick AlAsBi layer, the strain relaxation occurs when the Bi composition is larger than 6.5%. Flux ratio is calculated from Knudsen-cell model and Maxwell equation, according to the geometrical relationship of our equipment. The Bi incorporation increases with increasing the As-Al flux ratio as well as the Bi flux. The extrapolation lattice constant of hypothetic zincblende AlBi alloy is about 6.23 Å.
|
|
